Clinical Trial Update: A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) [Phase 2]

View source ↗

Summary

Phase II trial evaluating evolocumab plus nivolumab to bolster immunotherapy in metastatic renal cell carcinoma. The study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Evolocumab (evolocumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING